CR20210572A - Métodos y composiciones para editar ácido ribonucleicos (arn) - Google Patents
Métodos y composiciones para editar ácido ribonucleicos (arn)Info
- Publication number
- CR20210572A CR20210572A CR20210572A CR20210572A CR20210572A CR 20210572 A CR20210572 A CR 20210572A CR 20210572 A CR20210572 A CR 20210572A CR 20210572 A CR20210572 A CR 20210572A CR 20210572 A CR20210572 A CR 20210572A
- Authority
- CR
- Costa Rica
- Prior art keywords
- methods
- compositions
- editing
- rna
- rnas
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3519—Fusion with another nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/533—Physical structure partially self-complementary or closed having a mismatch or nick in at least one of the strands
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Abstract
La presente solicitud proporciona métodos para editar ARN mediante la introducción de un ARN de reclutamiento de desaminasas en una célula hospedera para la desaminación de una adenosina en un ARN objetivo; la presente solicitud proporciona además ARN de reclutamiento de desaminasas usados en los métodos de edición de ARN y composiciones que los comprenden.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2019082713 | 2019-04-15 | ||
CN2019129952 | 2019-12-30 | ||
PCT/CN2020/084922 WO2020211780A1 (en) | 2019-04-15 | 2020-04-15 | Methods and compositions for editing rnas |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20210572A true CR20210572A (es) | 2022-04-07 |
Family
ID=72837012
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20210572A CR20210572A (es) | 2019-04-15 | 2020-04-15 | Métodos y composiciones para editar ácido ribonucleicos (arn) |
Country Status (18)
Country | Link |
---|---|
US (2) | US20220307020A1 (es) |
EP (1) | EP3956449A4 (es) |
JP (1) | JP2022526455A (es) |
KR (1) | KR20220004674A (es) |
CN (1) | CN113939591A (es) |
AU (1) | AU2020259548B2 (es) |
BR (1) | BR112021020608A8 (es) |
CA (1) | CA3136735A1 (es) |
CL (1) | CL2021002695A1 (es) |
CO (1) | CO2021015214A2 (es) |
CR (1) | CR20210572A (es) |
EC (1) | ECSP21080618A (es) |
IL (1) | IL287248A (es) |
MX (1) | MX2021012645A (es) |
PE (1) | PE20212214A1 (es) |
SG (1) | SG11202111401RA (es) |
TW (1) | TW202043249A (es) |
WO (1) | WO2020211780A1 (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2017281497B2 (en) | 2016-06-22 | 2023-04-06 | Proqr Therapeutics Ii B.V. | Single-stranded RNA-editing oligonucleotides |
SG11202111401RA (en) | 2019-04-15 | 2021-11-29 | Edigene Inc | Methods and compositions for editing rnas |
WO2021008447A1 (en) | 2019-07-12 | 2021-01-21 | Peking University | Targeted rna editing by leveraging endogenous adar using engineered rnas |
JP2023504314A (ja) | 2019-12-02 | 2023-02-02 | シェイプ セラピューティクス インコーポレイテッド | 治療的編集 |
TW202138561A (zh) * | 2019-12-30 | 2021-10-16 | 大陸商博雅輯因(北京)生物科技有限公司 | 治療Usher綜合症的方法和其組合物 |
AU2020418228A1 (en) * | 2019-12-30 | 2022-08-18 | Edigene Therapeutics (Beijing) Inc. | Leaper technology based method for treating MPS IH and composition |
CN113528582B (zh) * | 2020-04-15 | 2022-05-17 | 博雅辑因(北京)生物科技有限公司 | 基于leaper技术靶向编辑rna的方法和药物 |
MX2022012985A (es) * | 2020-04-15 | 2022-11-09 | Edigene Therapeutics Beijing Inc | Metodo y farmaco para tratar el sindrome de hurler. |
CN116157520A (zh) * | 2020-05-26 | 2023-05-23 | 塑造治疗公司 | 用于基因组编辑的组合物和方法 |
CN117015605A (zh) * | 2021-01-12 | 2023-11-07 | 北京大学 | 使用工程化rna通过利用内源性adar进行靶向rna编辑 |
US20230194709A9 (en) * | 2021-06-29 | 2023-06-22 | Seagate Technology Llc | Range information detection using coherent pulse sets with selected waveform characteristics |
CN118202045A (zh) * | 2021-08-18 | 2024-06-14 | 北京大学 | 工程化的adar募集rna及其使用方法 |
WO2023143539A1 (en) * | 2022-01-28 | 2023-08-03 | Edigene Therapeutics (Beijing) Inc. | Engineered adar-recruiting rnas and methods of use thereof |
WO2023152371A1 (en) | 2022-02-14 | 2023-08-17 | Proqr Therapeutics Ii B.V. | Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia |
WO2024013361A1 (en) | 2022-07-15 | 2024-01-18 | Proqr Therapeutics Ii B.V. | Oligonucleotides for adar-mediated rna editing and use thereof |
WO2024013360A1 (en) | 2022-07-15 | 2024-01-18 | Proqr Therapeutics Ii B.V. | Chemically modified oligonucleotides for adar-mediated rna editing |
GB202215614D0 (en) | 2022-10-21 | 2022-12-07 | Proqr Therapeutics Ii Bv | Heteroduplex rna editing oligonucleotide complexes |
WO2024110565A1 (en) | 2022-11-24 | 2024-05-30 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis |
GB202218090D0 (en) | 2022-12-01 | 2023-01-18 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency |
WO2024121373A1 (en) | 2022-12-09 | 2024-06-13 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of cardiovascular disease |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK187280A (da) | 1980-04-30 | 1981-10-31 | Novo Industri As | Ruhedsreducerende middel til et fuldvaskemiddel fuldvaskemiddel og fuldvaskemetode |
US5773244A (en) | 1993-05-19 | 1998-06-30 | Regents Of The University Of California | Methods of making circular RNA |
JP6049623B2 (ja) | 2010-10-22 | 2016-12-21 | カッパーアールエヌエー,インコーポレイテッド | α‐L‐イズロニダーゼ(IDUA)への天然アンチセンス転写物の阻害によるIDUA関連疾患の治療 |
US9650627B1 (en) | 2012-07-19 | 2017-05-16 | University Of Puerto Rico | Site-directed RNA editing |
WO2015134812A1 (en) | 2014-03-05 | 2015-09-11 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa |
CN107532162A (zh) | 2014-12-12 | 2018-01-02 | 托德·M·伍尔夫 | 用于利用寡核苷酸编辑细胞中核酸的组合物和方法 |
PL3234134T3 (pl) | 2014-12-17 | 2020-12-28 | Proqr Therapeutics Ii B.V. | Ukierunkowana edycja rna |
JP6624743B2 (ja) | 2015-07-14 | 2019-12-25 | 学校法人福岡大学 | 部位特異的rna変異導入方法およびそれに使用する標的編集ガイドrnaならびに標的rna−標的編集ガイドrna複合体 |
DE102015012522B3 (de) * | 2015-09-26 | 2016-06-02 | Eberhard Karls Universität Tübingen | Verfahren und Substanzen zur gerichteten RNA-Editierung |
US10617707B2 (en) | 2016-04-25 | 2020-04-14 | Proqr Therapeutics Ii B.V. | Oligonucleotides to treat eye disease |
AU2017281497B2 (en) * | 2016-06-22 | 2023-04-06 | Proqr Therapeutics Ii B.V. | Single-stranded RNA-editing oligonucleotides |
NZ751483A (en) | 2016-09-01 | 2022-07-01 | Proqr Therapeutics Ii Bv | Chemically modified single-stranded rna-editing oligonucleotides |
WO2018041873A1 (en) | 2016-09-01 | 2018-03-08 | F. Hoffmann-La Roche Ag | Process for the preparation of (6s)-6-isopropyl-10-methoxy-9-(3-methoxypropoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid |
GB201616202D0 (en) | 2016-09-23 | 2016-11-09 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of eye deisease |
US11274300B2 (en) | 2017-01-19 | 2022-03-15 | Proqr Therapeutics Ii B.V. | Oligonucleotide complexes for use in RNA editing |
GB2574769A (en) | 2017-03-03 | 2019-12-18 | Univ California | RNA Targeting of mutations via suppressor tRNAs and deaminases |
CN110869498A (zh) | 2017-05-10 | 2020-03-06 | 加利福尼亚大学董事会 | 经由核递送crispr/cas9导向编辑细胞rna |
WO2019005886A1 (en) | 2017-06-26 | 2019-01-03 | The Broad Institute, Inc. | CRISPR / CAS-CYTIDINE DEAMINASE COMPOSITIONS, SYSTEMS AND METHODS FOR TARGETED EDITING OF NUCLEIC ACIDS |
AU2018338318B2 (en) | 2017-09-21 | 2022-12-22 | Massachusetts Institute Of Technology | Systems, methods, and compositions for targeted nucleic acid editing |
US11788088B2 (en) | 2017-09-26 | 2023-10-17 | The Board Of Trustees Of The University Of Illinois | CRISPR/Cas system and method for genome editing and modulating transcription |
EP3692145A4 (en) | 2017-10-04 | 2021-11-24 | The Broad Institute, Inc. | NUCLEIC ACID TARGETED EDITING SYSTEMS, METHODS AND COMPOSITIONS |
EP3728594A1 (en) | 2017-12-21 | 2020-10-28 | CRISPR Therapeutics AG | Materials and methods for treatment of usher syndrome type 2a |
WO2019158475A1 (en) | 2018-02-14 | 2019-08-22 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for rna editing |
BR112020019079A2 (pt) | 2018-03-23 | 2020-12-29 | Massachusetts Eye And Ear Infirmary | Abordagem de salto de éxon mediada por crispr/cas9 para síndrome de usher associada a ush2a |
WO2020001793A1 (en) * | 2018-06-29 | 2020-01-02 | Eberhard-Karls-Universität Tübingen | Artificial nucleic acids for rna editing |
CA3110998A1 (en) | 2018-09-06 | 2020-03-12 | The Regents Of The University Of California | Rna and dna base editing via engneered adar recruitment |
CA3115864A1 (en) | 2018-10-12 | 2020-04-16 | Peking University | Methods and compositions for editing rnas |
KR20210106527A (ko) | 2018-12-20 | 2021-08-30 | 페킹 유니버시티 | 바코드화 가이드 rna 구축물을 사용한 고효율의 유전자 스크리닝을 위한 조성물 및 방법 |
JP2022520080A (ja) | 2019-02-13 | 2022-03-28 | ビーム セラピューティクス インク. | 遺伝的疾患の治療用を含めアデノシンデアミナーゼ塩基エディターを用いて疾患関連遺伝子を編集する方法 |
CN109943586B (zh) | 2019-03-15 | 2021-02-26 | 上海交通大学 | 一种植物circRNA过表达载体及其构建方法 |
SG11202111401RA (en) | 2019-04-15 | 2021-11-29 | Edigene Inc | Methods and compositions for editing rnas |
EP3964579A4 (en) | 2019-04-30 | 2023-07-26 | EdiGene (GuangZhou) Inc. | METHOD OF PREDICTING THE EFFECTIVENESS OF THE TREATMENT OF HEMOGLOBINOPATHY |
WO2021008447A1 (en) | 2019-07-12 | 2021-01-21 | Peking University | Targeted rna editing by leveraging endogenous adar using engineered rnas |
KR20220053671A (ko) | 2019-09-04 | 2022-04-29 | 에디진 인크. | 오프 타겟 평가 기반의 유전자 편집 치료의 평가 방법 |
US20230027247A1 (en) | 2019-12-16 | 2023-01-26 | Edigene (Guangzhou) Inc. | Small molecule compounds for amplifying hematopoietic stem cells, and combination thereof |
TW202138561A (zh) | 2019-12-30 | 2021-10-16 | 大陸商博雅輯因(北京)生物科技有限公司 | 治療Usher綜合症的方法和其組合物 |
AU2020418228A1 (en) | 2019-12-30 | 2022-08-18 | Edigene Therapeutics (Beijing) Inc. | Leaper technology based method for treating MPS IH and composition |
KR20220122727A (ko) | 2019-12-31 | 2022-09-02 | 에디진 테라퓨틱스 (베이징) 인크. | Rna의 표적 편집을 위한 신규한 방법 |
DE102020126779A1 (de) | 2020-10-13 | 2022-04-14 | Fritsch Bakery Technologies GmbH & Co. KG | Teigverarbeitungsmaschine zum Bearbeiten von Produkten |
CN117015605A (zh) | 2021-01-12 | 2023-11-07 | 北京大学 | 使用工程化rna通过利用内源性adar进行靶向rna编辑 |
-
2020
- 2020-04-15 SG SG11202111401RA patent/SG11202111401RA/en unknown
- 2020-04-15 TW TW109112632A patent/TW202043249A/zh unknown
- 2020-04-15 CN CN202080029167.4A patent/CN113939591A/zh active Pending
- 2020-04-15 JP JP2021561885A patent/JP2022526455A/ja active Pending
- 2020-04-15 PE PE2021001716A patent/PE20212214A1/es unknown
- 2020-04-15 US US17/603,918 patent/US20220307020A1/en active Pending
- 2020-04-15 AU AU2020259548A patent/AU2020259548B2/en active Active
- 2020-04-15 WO PCT/CN2020/084922 patent/WO2020211780A1/en unknown
- 2020-04-15 CA CA3136735A patent/CA3136735A1/en active Pending
- 2020-04-15 BR BR112021020608A patent/BR112021020608A8/pt unknown
- 2020-04-15 EP EP20792124.8A patent/EP3956449A4/en active Pending
- 2020-04-15 MX MX2021012645A patent/MX2021012645A/es unknown
- 2020-04-15 KR KR1020217037218A patent/KR20220004674A/ko not_active Application Discontinuation
- 2020-04-15 CR CR20210572A patent/CR20210572A/es unknown
-
2021
- 2021-10-13 IL IL287248A patent/IL287248A/en unknown
- 2021-10-14 CL CL2021002695A patent/CL2021002695A1/es unknown
- 2021-10-14 US US17/501,954 patent/US11702658B2/en active Active
- 2021-11-11 CO CONC2021/0015214A patent/CO2021015214A2/es unknown
- 2021-11-15 EC ECSENADI202180618A patent/ECSP21080618A/es unknown
Also Published As
Publication number | Publication date |
---|---|
PE20212214A1 (es) | 2021-11-19 |
BR112021020608A2 (pt) | 2022-02-22 |
MX2021012645A (es) | 2021-11-12 |
US20220307020A1 (en) | 2022-09-29 |
CN113939591A (zh) | 2022-01-14 |
US11702658B2 (en) | 2023-07-18 |
BR112021020608A8 (pt) | 2023-03-21 |
CO2021015214A2 (es) | 2022-02-07 |
EP3956449A4 (en) | 2023-03-29 |
WO2020211780A1 (en) | 2020-10-22 |
KR20220004674A (ko) | 2022-01-11 |
AU2020259548B2 (en) | 2023-10-12 |
CA3136735A1 (en) | 2020-10-22 |
EP3956449A1 (en) | 2022-02-23 |
CL2021002695A1 (es) | 2022-07-01 |
US20220098587A1 (en) | 2022-03-31 |
AU2020259548A1 (en) | 2021-12-09 |
IL287248A (en) | 2021-12-01 |
ECSP21080618A (es) | 2021-12-30 |
SG11202111401RA (en) | 2021-11-29 |
JP2022526455A (ja) | 2022-05-24 |
TW202043249A (zh) | 2020-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021012645A (es) | Metodos y composiciones para editar acidos ribonucleicos (arn). | |
PH12021550805A1 (en) | Methods and Compositions for Editing RNAs | |
CR20220063A (es) | Edición de ácido ribonucleico (arn) dirigido aprovechando la adenosina desaminasa que actúa sobre ácido ribonucleico endógeno (adar) utilizando ácidos ribonucleicos (arn) modificados genéticamente | |
AU2017306676A8 (en) | Adenosine nucleobase editors and uses thereof | |
WO2019089884A3 (en) | Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy | |
WO2018209158A3 (en) | CRISPR / RNA GUIDED NUCLEASE SYSTEMS AND METHODS | |
AU2018320870A1 (en) | RNA targeting methods and compositions | |
WO2020117968A3 (en) | Polymerases, compositions, and methods of use | |
EP3619302A4 (en) | COMPOSITIONS AND METHODS OF GENEDITATION IN T CELLS USING CRISPR / CPF1 | |
AU2016262093A8 (en) | Enhancing endonuclease based gene editing in primary cells | |
MX2019011040A (es) | Composiciones y metodos para potenciar la expresion genica. | |
EP3699280A3 (en) | Novel cas9 systems and methods of use | |
AU2018262698A1 (en) | Expansion of gamma delta T cells, compositions, and methods of use thereof | |
NZ738689A (en) | Engineered crispr-cas9 compositions and methods of use | |
MX2020004541A (es) | Edicion de genes de celulas primarias. | |
WO2017115128A3 (en) | Vector-free delivery of gene editing proteins and compositions to cells and tissues | |
MX2021014861A (es) | Edicion genomica de reparacion dependiente de homologia mejorada. | |
MX2020003339A (es) | Arn guía de cpf1 modificado. | |
EP4235179A3 (en) | Detection, quantification and/or isolation of circulating tumor cells based on the expression of cd321 marker | |
EP4058597A4 (en) | SYSTEMS, METHODS AND COMPOSITIONS FOR GENERATING MULTIOMICS INFORMATION FROM INDIVIDUAL CELLS | |
BR112019007365A2 (pt) | métodos e composições para imunoterapia com tusc2 | |
WO2018057946A3 (en) | Tuning crispr/cas9 activity with chemically modified nucleotide substitutions | |
MX2021005564A (es) | Metodos y composiciones para inmunoterapia contra cancer. | |
MX2017015302A (es) | Agentes nucleosidos para la reduccion de la actividad perjudicial de los genes que contienen repeticiones de nucleotidos extendidas. | |
WO2019190590A3 (en) | Methods for genomic integration for kluyveromyces host cells |